BE893553A - Derives de la proline et procede pour les preparer - Google Patents

Derives de la proline et procede pour les preparer Download PDF

Info

Publication number
BE893553A
BE893553A BE0/208378A BE208378A BE893553A BE 893553 A BE893553 A BE 893553A BE 0/208378 A BE0/208378 A BE 0/208378A BE 208378 A BE208378 A BE 208378A BE 893553 A BE893553 A BE 893553A
Authority
BE
Belgium
Prior art keywords
emi
radical
compound
formula
residue
Prior art date
Application number
BE0/208378A
Other languages
English (en)
French (fr)
Inventor
S Tanaka
K Juromaru
Y Fujimura
I Matsunaga
T Iwaoka
N Obatake
J Aono
Y Hinohara
H Nakano
M Fukushima
H Nabata
K Sakai
S I Hata
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of BE893553A publication Critical patent/BE893553A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01D—MEASURING NOT SPECIALLY ADAPTED FOR A SPECIFIC VARIABLE; ARRANGEMENTS FOR MEASURING TWO OR MORE VARIABLES NOT COVERED IN A SINGLE OTHER SUBCLASS; TARIFF METERING APPARATUS; MEASURING OR TESTING NOT OTHERWISE PROVIDED FOR
    • G01D2205/00—Indexing scheme relating to details of means for transferring or converting the output of a sensing member
    • G01D2205/70—Position sensors comprising a moving target with particular shapes, e.g. of soft magnetic targets
    • G01D2205/77—Specific profiles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BE0/208378A 1981-06-19 1982-06-17 Derives de la proline et procede pour les preparer BE893553A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP56094002A JPS57209270A (en) 1981-06-19 1981-06-19 Proline derivative

Publications (1)

Publication Number Publication Date
BE893553A true BE893553A (fr) 1982-12-17

Family

ID=14098203

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/208378A BE893553A (fr) 1981-06-19 1982-06-17 Derives de la proline et procede pour les preparer

Country Status (5)

Country Link
JP (1) JPS57209270A (de)
AT (1) AT390619B (de)
BE (1) BE893553A (de)
SU (1) SU1272982A3 (de)
ZA (1) ZA823779B (de)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004017964A1 (en) 2002-08-19 2004-03-04 Pfizer Products Inc. Combination therapy for hyperproliferative diseases
WO2007062314A2 (en) 2005-11-23 2007-05-31 Bristol-Myers Squibb Company Heterocyclic cetp inhibitors
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
EP2392567A1 (de) 2005-10-21 2011-12-07 Bristol-Myers Squibb Company Benzothiazinderivate und ihre verwendung als lxr-modulatoren
WO2014170786A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
CN115819270A (zh) * 2021-09-17 2023-03-21 洛阳中科生物芯片技术有限公司 金刚烷胺半抗原、金刚烷胺抗原、制备方法以及金刚烷胺单克隆抗体及金刚烷胺检测试剂盒

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR73585B (de) * 1978-09-11 1984-03-26 Univ Miami
ZA802420B (en) * 1979-05-18 1981-04-29 Squibb & Sons Inc Aminoacyl derivatives of mercaptoacyl amino acids
PT70158A1 (en) * 1980-03-03 1982-03-01 Univ Miami Process for preparing anti-hypertensive agents

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004017964A1 (en) 2002-08-19 2004-03-04 Pfizer Products Inc. Combination therapy for hyperproliferative diseases
EP2392567A1 (de) 2005-10-21 2011-12-07 Bristol-Myers Squibb Company Benzothiazinderivate und ihre verwendung als lxr-modulatoren
WO2007062314A2 (en) 2005-11-23 2007-05-31 Bristol-Myers Squibb Company Heterocyclic cetp inhibitors
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
WO2014170786A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
CN115819270A (zh) * 2021-09-17 2023-03-21 洛阳中科生物芯片技术有限公司 金刚烷胺半抗原、金刚烷胺抗原、制备方法以及金刚烷胺单克隆抗体及金刚烷胺检测试剂盒

Also Published As

Publication number Publication date
JPS6313433B2 (de) 1988-03-25
ZA823779B (en) 1984-01-25
SU1272982A3 (ru) 1986-11-23
ATA238582A (de) 1989-11-15
AT390619B (de) 1990-06-11
JPS57209270A (en) 1982-12-22

Similar Documents

Publication Publication Date Title
EP0049658B1 (de) Substituierte Iminodisäuren, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
EP0318377B1 (de) Enantiomere Derivate von Aminosäure, Verfahren zu deren Herstellung und deren therapeutische Verwendung
EP0274453A2 (de) Collagenasehemmende Verbindungen, Herstellungsverfahren und Arzneimittel
EP0051020B1 (de) Substituierte Azabicyclooctancarboxylsäure, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
EP0031741A1 (de) Substituierte Iminosäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Enzym-Inhibitoren
EP0165919B1 (de) (R)-Alpha-ethyl-2-oxo-1-pyrrolidinacetamid
LU80596A1 (fr) Amides subsittues de l- et dl-phenylglycine,leur procede de production et compostition pharmaceutique les contenant
FR2460291A1 (fr) Nouveaux tripeptides agissant sur le systeme nerveux central et leur procede de preparation
EP0316218B1 (de) L-Prolin-Derivate, deren Herstellung und deren biologische Anwendungen
FR2667864A2 (fr) Derives de n-phenyl glycinamides, leur preparation et les medicaments les contenant.
LU86569A1 (fr) Composes inhibiteurs de l'enzyme de conversion de l'angiotensine
LU87262A1 (fr) Nouveaux derives de la somatostatine,leur preparation et leur utilisation comme medicaments
BE893553A (fr) Derives de la proline et procede pour les preparer
FR2533920A1 (fr) Tripeptide- et tetrapeptide-alkylamides a activite biologique, utiles comme medicaments et procedes pour leur preparation
EP1367061A1 (de) Verfahren für die Synthese von Perindopril und seiner pharmazeutischen annehmbaren Salzen
FR2548187A1 (fr) Composes d'organo-germanium et leurs utilisations therapeutiques en tant qu'inhibiteurs des enzymes qui degradent les peptides opioides
RU2017748C1 (ru) Производные нитратоалкановых кислот или их фармацевтически приемлемые соли
CA1310443C (fr) Derives de l'acide glutamique, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant
BE1001618A4 (fr) Peptides et derives peptidiques, leur preparation et leur utilisation comme medicaments.
EP0991650B1 (de) N-benzenesulfonyl-l-prolin-derivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung
FR2508040A1 (fr) Derives de proline, leur procede de preparation et medicament les contenant
EP0129461B1 (de) Derivate von Isoindoldicarbosäuren, deren Herstellung und deren Zusammensetzungen
FR2487341A1 (fr) Tripeptides inhibiteurs de l'enzyme de transformation de l'angiotensine
CH674009A5 (de)
EP0354108A1 (de) Aminosäuren und Peptide mit einem modifizierten Tyrosin, ihre Herstellung und ihre Verwendung als Medikamente

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: CHUGAI SEIYAKU K.K.

Effective date: 20000630